-
Je něco špatně v tomto záznamu ?
10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix
R Prymula, L Schuerman
Jazyk angličtina Země Velká Británie
Typ dokumentu přehledy
NLK
ProQuest Central
od 2002-06-01 do 2014-09-30
Health & Medicine (ProQuest)
od 2002-06-01 do 2014-09-30
Public Health Database (ProQuest)
od 2002-06-01 do 2014-09-30
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- Haemophilus influenzae imunologie MeSH
- hemofilové vakcíny imunologie škodlivé účinky MeSH
- kojenec MeSH
- kombinované vakcíny imunologie škodlivé účinky MeSH
- lidé MeSH
- pneumokokové vakcíny imunologie škodlivé účinky MeSH
- předškolní dítě MeSH
- sekundární imunizace metody MeSH
- Streptococcus pneumoniae imunologie MeSH
- vakcinace metody MeSH
- vakcíny konjugované imunologie škodlivé účinky MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
The global burden of disease due to Streptococcus pneumoniae remains high. The licensed 7-valent pneumococcal conjugate vaccine (7vCRM, Prevenar/Prevnar) has successfully reduced invasive disease in the USA, but serotype coverage is incomplete and some evidence suggests that serotype replacement has occurred. Recently, a new 10-valent pneumococcal nontypeable Haemophilus influenzae (NTHi) protein D (PD) conjugate vaccine (PHiD-CV, Synflorix) has been licensed in more than 40 countries, including Europe, for the prevention of invasive disease and acute otitis media (AOM) due to pneumococcus in infants and children. PHiD-CV is immunogenic in infants when administered as a three-dose primary vaccination in a range of schedules and has a safety profile comparable to that of 7vCRM. Additional serotypes in PHiD-CV (1, 5 and 7F) increase overall serotype coverage and improve coverage in specific age groups and against specific disease syndromes. The use of the PD carrier, which provided protection against AOM caused by NTHi in a large efficacy trial testing a prototype of the final vaccine formulation, suggests that PHiD-CV will also provide some protection against AOM due to NTHi.
Literatura.
- 000
- 02928naa a2200445 a 4500
- 001
- bmc12008585
- 003
- CZ-PrNML
- 005
- 20140519083355.0
- 008
- 120316s2009 xxk eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $d ABA008
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Prymula, Roman, $u Department of Epidemiology, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic. prymula@pmfhk.cz $d 1964- $7 nlk19990073741
- 245 10
- $a 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix / $c R Prymula, L Schuerman
- 504 __
- $a Literatura. $b 105
- 520 9_
- $a The global burden of disease due to Streptococcus pneumoniae remains high. The licensed 7-valent pneumococcal conjugate vaccine (7vCRM, Prevenar/Prevnar) has successfully reduced invasive disease in the USA, but serotype coverage is incomplete and some evidence suggests that serotype replacement has occurred. Recently, a new 10-valent pneumococcal nontypeable Haemophilus influenzae (NTHi) protein D (PD) conjugate vaccine (PHiD-CV, Synflorix) has been licensed in more than 40 countries, including Europe, for the prevention of invasive disease and acute otitis media (AOM) due to pneumococcus in infants and children. PHiD-CV is immunogenic in infants when administered as a three-dose primary vaccination in a range of schedules and has a safety profile comparable to that of 7vCRM. Additional serotypes in PHiD-CV (1, 5 and 7F) increase overall serotype coverage and improve coverage in specific age groups and against specific disease syndromes. The use of the PD carrier, which provided protection against AOM caused by NTHi in a large efficacy trial testing a prototype of the final vaccine formulation, suggests that PHiD-CV will also provide some protection against AOM due to NTHi.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a předškolní dítě $7 D002675
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a hemofilové vakcíny $x imunologie $x škodlivé účinky $7 D018073
- 650 02
- $a Haemophilus influenzae $x imunologie $7 D006193
- 650 02
- $a lidé $7 D006801
- 650 02
- $a sekundární imunizace $x metody $7 D007117
- 650 02
- $a kojenec $7 D007223
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a pneumokokové vakcíny $x imunologie $x škodlivé účinky $7 D022242
- 650 02
- $a Streptococcus pneumoniae $x imunologie $7 D013296
- 650 02
- $a vakcinace $x metody $7 D014611
- 650 02
- $a kombinované vakcíny $x imunologie $x škodlivé účinky $7 D017778
- 650 02
- $a vakcíny konjugované $x imunologie $x škodlivé účinky $7 D018074
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Schuerman, Lode
- 773 0_
- $t Expert Review of Vaccines $p Expert Rev Vaccines $g Roč. 8, č. 11 (2009), s. 1479-1500 $w MED00174438 $x 1210-0668
- 773 0_
- $p Expert Rev Vaccines $g 8(11):1479-500, 2009 Nov
- 910 __
- $a ABA008 $b x $y 4 $z 0
- 990 __
- $a 20120319124536 $b ABA008
- 991 __
- $a 20140519083537 $b ABA008
- 999 __
- $a ok $b bmc $g 901946 $s 765480
- BAS __
- $a 3
- BMC __
- $a 2009 $b 8 $c 11 $d 1479-1500 $m Expert review of vaccines $x MED00174438
- LZP __
- $a 2012-1Q10/jj
